Athenex's oral chemother­a­py for­mu­la­tion scores in piv­otal study; Gly­comine brings in $33M in Se­ries B haul

→ Athenex $AT­NX, whose plat­form tech­nol­o­gy is en­gi­neered to con­vert wide­ly-used in­tra­venous chemother­a­pies in­to oral drugs, said its oral for­mu­la­tion of pa­cli­tax­el met the main …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER